Search clinical trials for: Fludarabine, Cyclophosphamide

Total 4215 results

Wuhan Union Hospital, China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; SWOG Cancer Research...

Completed

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States, Canada, Puerto Rico, South Africa
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Leukemia

United States
European Organisation for Research and Treatment...

Unknown

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Leukemia

Belgium, Netherlands, Czech Republic, Hungary, Italy, Macedonia, The Former Yugoslav Republic of, Portugal
Celyad Oncology SA

Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Belgium, United States
German CLL Study Group

Completed

Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany, Austria
Inge Marie Svane

Recruiting

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Peritoneal Cancer | Metastatic Ovarian Cancer | Metastatic Fallopian Tube Cancer

Denmark
TC Biopharm

Completed

Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukemia

Czechia
Anhui Provincial Hospital

Recruiting

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia

China
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals

Not yet recruiting

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Breast Cancer | Triple Negative Breast Cancer | Relapse | Resistant Cancer

United States
Cooperative Study Group A for Hematology

Completed

Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT (CyFluCyATG)

Bone Marrow Failure Syndromes

Korea, Republic of
Tongji Hospital
Nanjing IASO Biotherapeutics Co.,Ltd

Recruiting

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System (CARTinNS)

Autoimmune Diseases of the Nervous System | Autoimmune Diseases | Myasthenia Gravis | Neuromyelitis Optica Spectrum Disorder | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Immune-Mediated Necrotizing Myopathy

China
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

Leukemia, Myelocytic, Acute

United States
The Korean Society of Pediatric Hematology Oncology

Unknown

Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)

Anemia, Aplastic

Korea, Republic of
Masonic Cancer Center, University of Minnesota

Active, not recruiting

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia

Leukemia

United States
German CLL Study Group

Terminated

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany
Institute of Cancer Research, United Kingdom
Australasian Leukaemia and Lymphoma Group

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

Lymphoma

Australia, United Kingdom
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Plasma Cell Tumors

China
Emory University

Completed

Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies

Hematologic Malignancies

United States
Glycostem Therapeutics BV

Recruiting

Registry of Patients Having Received oNKord®

AML

Switzerland, Germany
Wuhan Union Hospital, China
Beijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.

Recruiting

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

T-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin Lymphoma

China
Wuhan Union Hospital, China
Shanghai Simnova Biotechnology Co.,Ltd.

Recruiting

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Non Hodgkin's Lymphoma

China
The Korean Society of Pediatric Hematology Oncology

Unknown

Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)

Aplastic Anemia

Korea, Republic of
St. Jude Children's Research Hospital

Completed

Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia (AACD34)

Aplastic Anemia

United States
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
EdiGene Inc.
The First Affiliated Hospital of Henan University of Science and Technology; Changping Laboratory

Recruiting

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
Chinese PLA General Hospital

Recruiting

Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL

Non Hodgkin's Lymphoma

China
Genta Incorporated

Completed

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
Anhui Provincial Hospital

Recruiting

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

Hematologic Diseases

China
University of Chicago
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer

Kidney Cancer | Melanoma (Skin)

United States
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Lymphoma | Leukemia

China
HRYZ Biotech Co.

Recruiting

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Cervical Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Carcinoma of Penis | Carcinoma of Vulva | Carcinoma of Vagina

China
Institute of Hematology & Blood Diseases Hospital
Bejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...

Recruiting

Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Refractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, Childhood

China
Wuhan Union Hospital, China
Chengdu USino Technology Biology Co., Ltd

Recruiting

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

China
Beijing Immunochina Medical Science & Technology...

Unknown

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Leukemia

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

United States
Letolab

Not yet recruiting

A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor

Adult Solid Tumor
China Medical University, China
Shanghai First Song Therapeutics Co., Ltd

Recruiting

A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors

Solid Tumor

China
Asan Medical Center

Active, not recruiting

CyFluATG in Lower Risk MDS

Myelodysplastic Syndromes

Korea, Republic of
Beijing Immunochina Medical Science & Technology...

Completed

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Leukemia

China
Cabaletta Bio

Recruiting

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy

Idiopathic Inflammatory Myopathy | Dermatomyositis | Immune-Mediated Necrotizing Myopathy | Anti-Synthetase Syndrome

United States
HRYZ Biotech Co.

Recruiting

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Cervical Cancer | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | Anal Carcinoma | Vagina Tumor | Carcinoma of Penis | Carcinoma of Vulva

China
The Christie NHS Foundation Trust

Terminated

A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy (CD19)

CD19 Positive Non-Hodgkin Lymphoma

United Kingdom
German CLL Study Group
University of Cologne; MedacSchering Onkologie

Completed

Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

B-cell Chronic Lymphocytic Leukemia

Germany
Sun Yat-sen University
Fudan University; West China Hospital; Peking University Cancer Hospital & Institute and other collaborators

Unknown

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

Mantle Cell Lymphoma Recurrent

China
Fudan University

Recruiting

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Solid Tumor

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China

Search clinical trials for: Fludarabine, Cyclophosphamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations